Education
About Us
Working with TipRanks
Follow Us
Cormedix (CRMD)
NASDAQ:CRMD
Top Page
Cormedix
(NASDAQ:CRMD)
Select Model
Select Model
Rating:64Neutral
Price Target:
$7.00
▲(9.89% Upside)
Action:ReiteratedDate:03/07/26
The score is driven primarily by sharply improved 2025 financial performance and cash generation, tempered by sustainability concerns. Technicals materially detract due to a clear downtrend and weak momentum signals. Valuation is supportive via a low P/E, while earnings-call guidance and catalysts are balanced by significant reimbursement-driven pricing and concentration risks.
Positive Factors
Cash generation strength
A dramatic shift to strong operating and free cash flow in 2025 materially improves durable liquidity and self-funding capacity. Sustained positive cash conversion enhances ability to fund clinical programs, absorb reimbursement shocks, service debt, and support buybacks or targeted M&A without immediate external financing.
High margin, profitable 2025 performance
The very high gross and net margins in 2025 indicate a highly profitable product mix and scalable commercial model if maintained. Durable margin expansion supports reinvestment in trials and commercialization, improves return on invested capital and provides a cushion versus pricing pressure from reimbursement transitions.
Meaningful pipeline catalysts
Near-term Phase III readouts (RIZEAO top-line due Q2 2026) represent structural upside beyond DefenCath, potentially diversifying revenue and reducing single-product dependency. Successful readouts and label expansion could create multi-year growth levers and materially expand the addressable market.
Negative Factors
Reimbursement transition risk
The TDAPA-to-bundled reimbursement change is a structural industry shift that reduces per-unit reimbursement and can permanently compress realized selling price. This materially weakens revenue durability for DefenCath absent durable contracting wins, legislative relief, or alternative reimbursement paths.
Customer concentration
Heavy reliance on three large customers creates persistent execution and pricing risk: contract renewal leverage, payor/provider consolidation, or a single-account volume shift could materially reduce sales. Concentration limits pricing power and raises the long-term revenue volatility profile.
Cost base and sustainability concerns
A sharp, structural increase in operating expenses following the Melinta acquisition and expanded trials raises the breakeven threshold. If reimbursement-driven price erosion reduces DefenCath revenue, higher fixed costs could pressure margins and free cash flow, testing the durability of 2025 profitability.
Cormedix (CRMD) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$503.55M
Dividend YieldN/A
Average Volume (3M)1.62M
Price to Earnings (P/E)5.1
Beta (1Y)1.52
Revenue Growth1647.67%
EPS GrowthN/A
CountryUS
Employees64
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.16
Shares Outstanding79,050,390
10 Day Avg. Volume1,990,124
30 Day Avg. Volume1,615,820
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)2.07
Price to Sales (P/S)2.69
P/FCF Ratio4.85
Enterprise Value/Market Cap1.00
Enterprise Value/Revenue1.61
Enterprise Value/Gross Profit1.82
Enterprise Value/Ebitda3.03
Forecast
1Y Price Target
$13.25Price Target Upside108.01% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)0.92
Revenue Forecast (FY)$308.66M
Cormedix Business Overview & Revenue Model
Company DescriptionCorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
How the Company Makes MoneyCorMedix primarily generates revenue through the commercialization of its lead product, DefenCath, once it receives regulatory approval. The company anticipates earning money by selling DefenCath to healthcare providers, dialysis centers, and hospitals. CorMedix's revenue model also includes potential partnerships and licensing agreements with other pharmaceutical companies, which can provide milestone payments and royalties. Additionally, CorMedix may receive governmental or institutional grants to support its research and development efforts, further contributing to its financial resources.
Cormedix Earnings Call Summary
Earnings Call Date:Mar 05, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 07, 2026
Earnings Call Sentiment Neutral
The call balanced several strong operational and financial achievements — including the Melinta acquisition, realization of $35M synergies, robust pro forma revenue ($401.3M), healthy cash (~$148.5M) and a clear pipeline catalyst with RIZEAO top-line data expected in Q2 2026 — against meaningful near-term headwinds tied to the TDAPA-to-bundle reimbursement transition, expected price erosion for DEFENCATH, customer concentration risk, and materially higher operating expenses following the merger. Management offered conservative guidance that reflects those reimbursement risks while preserving upside potential from Medicare Advantage contracting, inpatient adoption, and RIZEAO/TPN development programs. On balance, the positives around completed integration, liquidity, and upcoming clinical catalysts are offset by significant reimbursement and concentration risks that could materially pressure DEFENCATH revenue absent favorable contracting or legislative outcomes.Q4-2025 Updates
Positive Updates
Record Annual DEFENCATH Sales
DEFENCATH generated $258.8 million in net sales for 2025 (reported as "just under $260,000,000"), representing the company's largest single-product revenue contribution for the year.
Acquisition of Melinta and Achieved Synergies
Closed acquisition of Melinta Therapeutics (08/29/2025) and realized targeted annual synergies of $35,000,000 during 2025; Melinta contributed $37.4 million to Q4 2025 revenue.
Strong Quarterly and Pro Forma Revenue
Q4 2025 revenue was $128.6 million (DEFENCATH $91.2M; Melinta $37.4M). Pro forma full-year 2025 revenue (combined CorMedix + Melinta) was $401.3 million, in line with prior guidance.
Affirmed 2026 and 2027 Financial Guidance
Affirmed 2026 DEFENCATH guidance of $150M–$170M and 2027 DEFENCATH guidance of $100M–$125M. Company also affirmed full-year 2026 consolidated revenue guidance of $300M–$320M and adjusted EBITDA of $100M–$125M.
Strong Adjusted EBITDA and Net Income
Q4 adjusted EBITDA was $77.2 million (within guidance). CorMedix recognized net income of $14.0 million for 2025 and pre-tax Q4 income of $56.4 million (an increase of $43.0M vs. 2024).
Healthy Liquidity and Operating Cash Flow
Ended Q4 with $148.5 million in cash, cash equivalents, and short-term investments; operating cash flow in the quarter was nearly $100 million.
Clinical Milestones and Pipeline Value
Phase III RESPECT (RIZEAO prophylaxis) completed enrollment September 2025 with database lock expected March 2026 and top-line data anticipated in Q2 2026. Company estimates RIZEAO market opportunity at ~$2.5 billion across indications and DEFENCATH in TPN at $500M–$750M.
Progress on DEFENCATH TPN Program and NEUTROGUARD Enrollment
Phase III NEUTROGUARD (DEFENCATH for CLABSI prevention in TPN patients) is ~30% enrolled toward the minimum target of 90 patients; study completion anticipated in early 2027.
Workforce and Integration Progress
Headcount increased from ~100 to just under 200 employees post-merger (approximately 100% growth), reflecting integration and scaling to support commercial expansion. Management also initiated an active share repurchase program.
Negative Updates
Reimbursement Transition (TDAPA → Bundled Add-On) and Expected Price Erosion
On July 1, 2026 DEFENCATH TDAPA reimbursement will transition to a bundled add-on mechanism, which management expects will cause price erosion and front-loaded 2026 revenue with meaningful price pressure in Q4 2026.
Projected DEFENCATH Revenue Decline vs. 2025 Peak
2026 DEFENCATH guidance ($150M–$170M) implies a substantial decrease vs. 2025 DEFENCATH sales ($258.8M). Using midpoints, the implied year-over-year decline is roughly 38% (from $258.8M to ~$160M). 2027 guidance midpoint (~$112.5M) implies ~56% decline vs. 2025.
Sharp Increase in Operating Expenses
Q4 2025 operating expenses were $48.2 million vs. $17.1 million in Q4 2024 — an increase of approximately 182% (driven by combined organization costs, merger-related charges and expanded clinical investment).
Customer Concentration Risk
DEFENCATH volumes are heavily concentrated: one large LDO plus two mid-sized operators account for the vast majority of volume (management stated ~90% of volume among the three mid-sized/large accounts), creating exposure to contract/pricing changes or customer churn.
Legislative and Reimbursement Uncertainty
Efforts to extend TDAPA or achieve favorable retroactive reimbursement are uncertain and timing-dependent (bill attachment, geopolitical factors such as the war in the Middle East). This creates material uncertainty around near-term reimbursement outcomes.
NEUTROGUARD Enrollment and Timeline Risk
NEUTROGUARD is only ~30% enrolled toward minimum enrollment; study completion expected early 2027 but remains dependent on improved enrollment rates (additional sites in Turkey being added).
Tax Expense and Non-Cash Impacts
2025 net income was impacted by $42.4 million of tax expense (majority non-cash), related to utilization of deferred tax assets, which complicates GAAP profitability interpretation.
Near-Term Cash Flow Headwinds
Management flagged potential near-term cash impacts from inventory stockpiling for tech transfers and the payment of large accrued rebates in early 2026 despite strong Q4 operating cash flow.
Company Guidance
Management affirmed 2026 DEFENCATH guidance of $150–$170M and 2027 DEFENCATH guidance of $100–$125M, and reiterated full‑year 2026 company guidance of $300–$320M revenue and $100–$125M adjusted EBITDA; they expect 2026 revenue to be front‑loaded in H1 with price erosion in Q4 (TDAPA converts to a bundled add‑on July 1) and anticipate a higher net selling price in 2027 versus Q3 2026 (CMS methodology permitting). For context, 2025 pro forma revenue was $401.3M with DEFENCATH net sales of $258.8M (peak sales just under $260M); Q4 revenue was $128.6M (DEFENCATH $91.2M; Melinta $37.4M) and Q4 adjusted EBITDA was $77.2M; 2025 net income was $14.0M, pre‑tax Q4 income $56.4M, cash and short‑term investments $148.5M, operating cash flow in the quarter ~ $100M, and $35.0M of acquisition synergies were realized in 2025. Key pipeline and market metrics: RESPECT Phase III top‑line for RIZEAO due Q2 2026; NEUTROGUARD ~30% enrolled toward a 90‑patient minimum (adaptive to 200; interim after 15 CLABSI events; completion expected early 2027); estimated market opportunities of ~$2.5B for RIZEAO and $0.5–$0.75B for DEFENCATH in TPN.Cormedix Financial Statement Overview
Summary
Financials show a major 2025 turnaround: revenue ramped sharply with high margins and strong profitability, and operating/free cash flow turned strongly positive. The key offset is durability risk given multi-year losses and cash burn before 2025 and the magnitude of the year-over-year swing.Income Statement
Results show a sharp inflection: revenue surged from ~$43.5M (2024) to ~$311.7M (2025), with very strong profitability in 2025 (gross margin ~88% and net margin ~52%) and positive net income (~$163.1M) versus losses in prior years. The main weakness is volatility and limited consistency—2020–2024 were loss-making with negative operating profitability, so the sustainability of the 2025 step-change remains a key risk.78
Positive
Balance Sheet
The balance sheet strengthened meaningfully, with equity rising to ~$405.3M (2025) and a moderate leverage profile (debt-to-equity ~0.37) despite debt increasing to ~$148.9M. Returns improved substantially in 2025 (return on equity ~40%), but prior years showed negative returns and a much smaller debt load—so investors should watch whether the higher leverage remains well-supported if profitability normalizes.74
Positive
Cash Flow
Cash generation improved dramatically in 2025, with operating cash flow and free cash flow both around ~$175.0M versus sizable outflows in 2020–2024. Cash conversion is strong in 2025, with free cash flow roughly matching net income (about 1.0x), but the weakness is the historical pattern of sustained cash burn and the magnitude of the year-over-year swing, which increases confidence risk if 2025 proves non-recurring.82
Very Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 311.71M | 43.47M | 0.00 | 65.41K | 190.94K |
| Gross Profit | 275.75M | 40.28M | -205.56K | 61.67K | 42.00K |
| EBITDA | 165.13M | -18.98M | -46.23M | -30.05M | -29.38M |
| Net Income | 163.06M | -17.93M | -46.34M | -29.70M | -28.21M |
Balance Sheet | |||||
| Total Assets | 826.14M | 118.85M | 82.06M | 62.04M | 68.95M |
| Cash, Cash Equivalents and Short-Term Investments | 149.52M | 51.69M | 76.03M | 59.02M | 65.70M |
| Total Debt | 148.91M | 517.01K | 667.63K | 802.43K | 923.80K |
| Total Liabilities | 420.83M | 34.19M | 11.92M | 6.98M | 6.15M |
| Stockholders Equity | 405.31M | 84.66M | 70.14M | 55.06M | 62.80M |
Cash Flow | |||||
| Free Cash Flow | 172.79M | -50.73M | -38.74M | -24.58M | -22.58M |
| Operating Cash Flow | 175.05M | -50.61M | -38.41M | -24.36M | -21.16M |
| Investing Cash Flow | -308.43M | 21.23M | -17.06M | -3.71M | -9.13M |
| Financing Cash Flow | 238.45M | 26.32M | 55.92M | 17.90M | 41.76M |
Cormedix Technical Analysis
Negative
6.37
Price Trends
7.35
Negative
9.24
Negative
10.77
Negative
Market Momentum
-0.35
Negative
36.14
Neutral
39.12
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CRMD, the sentiment is Negative. The current price of 6.37 is below the 20-day moving average (MA) of 6.81, below the 50-day MA of 7.35, and below the 200-day MA of 10.77, indicating a bearish trend. The MACD of -0.35 indicates Negative momentum. The RSI at 36.14 is Neutral, neither overbought nor oversold. The STOCH value of 39.12 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CRMD.
Cormedix Risk Analysis
Cormedix disclosed 42 risk factors in its most recent earnings report. Cormedix reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Cormedix Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | $503.55M | 5.14 | 58.50% | ― | 1647.67% | ― | |
54 Neutral | $1.32B | ― | -156.98% | ― | ― | -38.04% | |
53 Neutral | $1.22B | -8.82 | -67.26% | ― | -36.36% | -945.72% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $1.30B | -5.79 | -39.69% | ― | -27.61% | -69.49% | |
46 Neutral | $835.29M | -4.22 | -141.99% | ― | ― | 31.16% | |
41 Neutral | $817.38M | -28.12 | -50.20% | ― | 116.64% | 47.93% |
* Healthcare Sector Average
CRMD
Cormedix
6.37
-4.49
-41.34%
ABUS
Arbutus Biopharma
4.25
0.94
28.40%
IMTX
Immatics
9.68
4.38
82.64%
TSHA
Taysha Gene Therapies
4.45
2.75
161.76%
SANA
Sana Biotechnology
3.13
0.87
38.50%
ZBIO
Zenas BioPharma, Inc.
23.03
14.51
170.31%
Cormedix Corporate Events
Business Operations and StrategyFinancial Disclosures
CorMedix Reaffirms DefenCath 2027 Sales and Outlook
Positive
Mar 6, 2026
On March 6, 2026, CorMedix, Inc. released an updated investor presentation outlining its institutional-focused pharmaceutical portfolio and reaffirmed its previously issued sales guidance for DefenCath in 2027. The company corrected an inadvertent lower range mentioned on its March 5, 2026 earnings call and reiterated that it expects full-year 2027 DefenCath sales to fall between $100 million and $140 million, underscoring management’s confidence in the product’s growth trajectory.
The presentation also highlighted CorMedix’s broader growth and financial outlook, including 2026 company-wide revenue guidance of $300 million to $320 million and adjusted EBITDA of $100 million to $125 million, supported by DefenCath and a suite of anti-infective and cardiovascular products. For investors and other stakeholders, the reaffirmed guidance and detailed projections signal continued emphasis on DefenCath as a key revenue driver within a diversified hospital and acute-care platform, while clarifying any confusion created by the prior earnings call commentary.
The most recent analyst rating on (CRMD) stock is a Hold with a $7.00 price target. To see the full list of analyst forecasts on Cormedix stock, see the CRMD Stock Forecast page.
Business Operations and StrategyExecutive/Board ChangesFinancial Disclosures
Cormedix Issues Strong Preliminary Q4 Results, Updates Outlook
Positive
Jan 8, 2026
On January 5, 2026, CorMedix entered into an amended and restated employment agreement with Chief Executive Officer Joseph Todisco that raised his base salary to $750,000 as of January 1, 2026, increased his target bonus, expanded his eligibility for equity awards, and confirmed his appointment as chairman of the board effective January 8, 2026, alongside enhanced severance protections and post-employment restrictive covenants that further consolidate leadership stability at the company. Also on January 8, 2026, CorMedix reported preliminary unaudited fourth-quarter 2025 net revenue of about $127 million and full-year net revenue of approximately $310 million, with pro forma full-year revenue of roughly $400 million reflecting its Melinta acquisition, adjusted EBITDA of $77–81 million in the fourth quarter, and cash and short-term investments of around $148 million, while highlighting strong DefenCath utilization, looming Medicare reimbursement-driven price pressure in the second half of 2026, and planned Phase 3 readouts for REZZAYO and DefenCath that, together with operational synergies and 2026 revenue and EBITDA guidance, underscore its transition into a diversified anti-infective player with multiple growth levers and meaningful financial scale.
The most recent analyst rating on (CRMD) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Cormedix stock, see the CRMD Stock Forecast page.
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.